Clinical progress of cadonilimab in the treatment of malignant tumor
Cadonilimab is a programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) bispecific antibody independently developed in China, and is also the world's first approved PD-1/CTLA-4 bispecific antibody. By simultaneously blocking two immunosuppressive pathways, PD-1/CTLA-...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of New Medicine
2025-06-01
|
| Series: | Yixue xinzhi zazhi |
| Subjects: | |
| Online Access: | https://yxxz.whuznhmedj.com/futureApi/storage/attach/2506/2jEgrx7aeo08ZFLB0UW9aFOlYtOGLtmZ1McDMd9S.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|